NCT05653193View on ClinicalTrials.gov

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 17, 2024

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Chronic Pulmonary AspergillosisAspergillosis
Interventions
DRUG

Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care

Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.

DRUG

Antifungals as standard of care

Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.

Trial Locations (1)

M23 9LT

RECRUITING

Manchester University NHS Foundation Trust, Manchester

All Listed Sponsors
lead

Manchester University NHS Foundation Trust

OTHER_GOV